Neurocrine Biosciences Inc (NBIX): Christopher Flint Obrien , Chief Medical Officer of Neurocrine Biosciences Inc sold 25,000 shares on May 16, 2016. The Insider selling transaction was reported by the company on May 18, 2016 to the Securities and Exchange Commission. The shares were sold at $45.00 per share for a total value of $1,125,000.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 13, 2016, Kyle Gano (Chief Business Development Off) sold 41,770 shares at $43.77 per share price.On Apr 8, 2016, Christopher Flint Obrien (Chief Medical Officer) sold 25,000 shares at $45.00 per share price.Also, On Feb 4, 2016, Dimitri E. Grigoriadis (Chief Research Officer) sold 1,375 shares at $37.98 per share price.On Feb 4, 2016, Kevin Charles Gorman (President and CEO) sold 3,125 shares at $38.04 per share price.
Neurocrine Biosciences: On Thursday, May 19, 2016 heightened volatility was witnessed in Neurocrine Biosciences which led to swings in the share price. The shares opened for trading at $45.48 and hit $47.3 on the upside , eventually ending the session at $46.92, with a gain of 2.80% or 1.28 points. The heightened volatility saw the trading volume jump to 11,78,315 shares. The 52-week high of the share price is $58.46 and the company has a market cap of $4,066 M . The 52-week low of the share price is at $31.25.
Neurocrine Biosciences Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine based diseases and disorders. The Company’s two lead late-stage clinical programs are elagolix a gonadotropin releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc. (AbbVie) and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. elagolix is in clinical trials for the treatment of Endometriosis and Uterine Fibroids. VMAT2 (NBI-98854) is a VMAT2 inhibitor in clinical trials for the treatment of tardive dyskinesia. Corticotropin-Releasing Factor (CRF) receptor antagonist (NBI-77860) is indicated for the treatment of Classic Congenital Adrenal Hyperplasia. NBI-77860 is a selective orally-active non-peptide CRF receptor antagonist.